Literature DB >> 15836963

Where do triptans act in the treatment of migraine?

Andrew H Ahn1, Allan I Basbaum.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15836963      PMCID： PMC1850935          DOI： 10.1016/j.pain.2005.03.008

Source DB:  PubMed          Journal:  Pain        ISSN： 0304-3959            Impact factor:   6.961


× No keyword cloud information.
  33 in total

1.  Evidence for postjunctional serotonin (5-HT1) receptors in the trigeminocervical complex.

Authors:  P J Goadsby; S Akerman; R J Storer
Journal:  Ann Neurol       Date:  2001-12       Impact factor: 10.422

Review 2.  Deconstructing migraine headache into peripheral and central sensitization.

Authors:  R Burstein
Journal:  Pain       Date:  2001-01       Impact factor: 6.961

3.  Rizatriptan has central antinociceptive effects against durally evoked responses.

Authors:  M J Cumberbatch; R G Hill; R J Hargreaves
Journal:  Eur J Pharmacol       Date:  1997-06-05       Impact factor: 4.432

4.  Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine.

Authors:  B Gomez-Mancilla; N R Cutler; M T Leibowitz; E L Spierings; J A Klapper; S Diamond; J Goldstein; T Smith; J R Couch; J Fleishaker; N Azie; D E Blunt
Journal:  Cephalalgia       Date:  2001-09       Impact factor: 6.292

5.  Atypical facial pain: a double-blind placebo-controlled crossover pilot study of subcutaneous sumatriptan.

Authors:  S D Harrison; S A Balawi; C Feinmann; M Harris
Journal:  Eur Neuropsychopharmacol       Date:  1997-05       Impact factor: 4.600

6.  Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose comparison study. The Sumatriptan Cluster Headache Study Group.

Authors:  K Ekbom; I Monstad; A Prusinski; J A Cole; A J Pilgrim; D Noronha
Journal:  Acta Neurol Scand       Date:  1993-07       Impact factor: 3.209

7.  Inhibition of inflammation-induced thermal hypersensitivity by sumatriptan through activation of 5-HT(1B/1D) receptors.

Authors:  S Bingham; P T Davey; M Sammons; P Raval; P Overend; A A Parsons
Journal:  Exp Neurol       Date:  2001-01       Impact factor: 5.330

8.  Is myofascial pain of the temporal muscles relieved by oral sumatriptan? A cross-over pilot study.

Authors:  Thuan T T Dao; James P Lund; Guy Rémillard; Gilles J Lavigne
Journal:  Pain       Date:  1995-08       Impact factor: 6.961

9.  Changes in cerebral blood flow velocity after treatment with sumatriptan or placebo and implications for the pathophysiology of migraine.

Authors:  V Limmroth; A May; P Auerbach; G Wosnitza; T Eppe; H C Diener
Journal:  J Neurol Sci       Date:  1996-06       Impact factor: 3.181

10.  Comparison of the effects of sumatriptan and the NK1 antagonist CP-99,994 on plasma extravasation in Dura mater and c-fos mRNA expression in trigeminal nucleus caudalis of rats.

Authors:  S L Shepheard; D J Williamson; J Williams; R G Hill; R J Hargreaves
Journal:  Neuropharmacology       Date:  1995-03       Impact factor: 5.250
View more
  37 in total

1.  5-HT(1B) receptors inhibit glutamate release from primary afferent terminals in rat medullary dorsal horn neurons.

Authors:  I-S Choi; J-H Cho; C-H An; J-K Jung; Y-K Hur; J-K Choi; I-S Jang
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

Review 2.  The pharmacotherapy of chronic pain: a review.

Authors:  Mary E Lynch; C Peter N Watson
Journal:  Pain Res Manag       Date:  2006       Impact factor: 3.037

3.  Is migraine a lateralization defect?

Authors:  Jani Kaaro; Timo Partonen; Paulami Naik; Nouchine Hadjikhani
Journal:  Neuroreport       Date:  2008-08-27       Impact factor: 1.837

4.  Tissue injury regulates serotonin 1D receptor expression: implications for the control of migraine and inflammatory pain.

Authors:  Andrew H Ahn; Allan I Basbaum
Journal:  J Neurosci       Date:  2006-08-09       Impact factor: 6.167

5.  Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting.

Authors:  Anne-Sophie Wattiez; Levi P Sowers; Andrew F Russo
Journal:  Expert Opin Ther Targets       Date:  2020-02-13       Impact factor: 6.902

6.  Effect of CGRP and sumatriptan on the BOLD response in visual cortex.

Authors:  Mohammad S Asghar; Adam E Hansen; Henrik B W Larsson; Jes Olesen; Messoud Ashina
Journal:  J Headache Pain       Date:  2012-01-14       Impact factor: 7.277

7.  NOP receptor agonist attenuates nitroglycerin-induced migraine-like symptoms in mice.

Authors:  Katarzyna M Targowska-Duda; Akihiko Ozawa; Zachariah Bertels; Andrea Cippitelli; Jason L Marcus; Hanna K Mielke-Maday; Gilles Zribi; Amanda N Rainey; Brigitte L Kieffer; Amynah A Pradhan; Lawrence Toll
Journal:  Neuropharmacology       Date:  2020-03-06       Impact factor: 5.250

Review 8.  Migraine Treatment: Current Acute Medications and Their Potential Mechanisms of Action.

Authors:  Jonathan Jia Yuan Ong; Milena De Felice
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

Review 9.  Does sumatriptan cross the blood-brain barrier in animals and man?

Authors:  Peer Carsten Tfelt-Hansen
Journal:  J Headache Pain       Date:  2009-12-10       Impact factor: 7.277

10.  Reversal of inflammatory and noninflammatory visceral pain by central or peripheral actions of sumatriptan.

Authors:  Louis P Vera-Portocarrero; Michael H Ossipov; Tamara King; Frank Porreca
Journal:  Gastroenterology       Date:  2008-07-03       Impact factor: 22.682
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.